Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies

Michael H. Rivner, Mamatha Pasnoor, Mazen M. Dimachkie, Richard J. Barohn, Lin Mei

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Around 20% of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30% to 40% of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.

Original languageEnglish (US)
Pages (from-to)293-310
Number of pages18
JournalNeurologic Clinics
Issue number2
StatePublished - May 2018


  • Agrin
  • Cortactin
  • LRP4
  • MuSK
  • Myasthenia gravis
  • Rapsyn

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies'. Together they form a unique fingerprint.

Cite this